The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1141
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Bristol-Myers Squibb (nivolumab)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- British Liver Trust
- Professional groups
- Association of Cancer Physicians
- British Association of the Study of the Liver
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- Evidence review group
- Warwick Evidence
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services committee
- Relevant research groups
- Foundation for Liver Research
- Institute of Cancer Research
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 15 September 2017 | Suspended: EMA website. The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma. We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website. The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 15 September 2017 | The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma. We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website. The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 15 May 2017 | Invitation to participate |
| 07 March 2017 - 28 March 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 March 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual